Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.63
(
1.92%
)
Bitcoin
71,081.44
(
-0.22%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 177608

Saturday, 09/27/2014 3:50:05 PM

Saturday, September 27, 2014 3:50:05 PM

Post# of 257257
AZN reports early data for anti-PD-1/CTLA4 combination of MEDI4736 + Tremelimumab:

http://in.reuters.com/article/2014/09/27/us-health-cancer-astrazeneca-idINKCN0HM0AD20140927

Tremelimumab, the anti-CTLA4 drug in the combination, was licensed from PFE in 2011(#msg-67624944).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now